Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Aggie who wrote (630)	6/5/1999 9:49:00 AM
From: JDN	Read Replies (1) \| Respond to of 783

Dear Aggie and all: Yes, I have been puzzled with BCHE shareholder value. My son just graduated with a degree in MicroBiology and Cell Science. I had him read the annual report and he told me stick with this stock, what they are working on is the hottest items right now being discussed a lot in the research centers. I have come to the conclusion that the problem is that they gave too much away in the marketing of the drugs which accounts for the lousy stock price. From their reports it seems they intend, in the future, to market themselves as much as they can. Hopefully, eventually this will pay off. Comments anyone?? JDN